Supplemental Data

Integrity® bare-metal coronary stent-induced platelet and endothelial cell activation results in a higher risk of restenosis compared to Xience® everolimus-eluting stents in stable angina patients

Tibor Szük¹, Zsolt Fejes², Ildikó Beke Debreceni², Adrienne Kerényi², István Édes¹, János Kappelmayer², Béla Nagy Jr^{2,*}

¹Institute of Cardiology, ²Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

Supplementary Table I. Procedural and lesion characteristics in patients with and without in-stent restenosis. There was no statistically significant alteration in various procedural and lesion characteristics between those with and without in-stent restenosis. MLD: Minimal Lumen Diameter.

Procedure and lesion characteristics	BMS without restenosis (n=22)	BMS with restenosis (n=6)	P-value
Direct stenting, n (%)	9 (43)	3 (50)	0.52
Pre-dilatation pressure (atm)	5.8±7.6	7.3±8.0	0.69
Implantation pressure (atm)	15.3±2.3	16.4±1.5	0.24
Lesion length (mm)	21.6±11.4	26.5±15.4	0.49
Vessel diameter (mm)	2.95±0.30	2.87±0.25	0.54
Calcification (no/mild/moderate/severe) (n)	8/8/3/1	2/1/3/0	0.31
Diameter stenosis (%)	81±5.7	86.6±7.5	0.13
Final MLD (mm)	2.99±0.32	2.92±0.21	0.59

Supplementary Table II. The results of stress ECG test after 6 months in BMS subjects without restenosis and all DES patients. No significant difference was found in the maximal ST segment depression at ST80, the exercise capacity and the time to ending between these two study groups. ST80: the point that is 80 msec from the J point; METS: metabolic equivalents; * marks the depression of 0.1 mV (1 mm) or more at ST80. All these patients underwent coronarography with normal results.

6 month stress ECG test results (bicycle ergometer)	BMS without restenosis (n=22)	DES without restenosis (n=21)	P-value
Maximal ST segment depression at ST80 (mV)	0.08±0.015	0.06±0.036	0.44
Positive result* (% , n)	9.09 (2)	9.52 (2)	
Exercise capacity (METS)	5.4±3.2	5.7±2.6	0.51
Reason for ending			
Reached the maximal heart rate	19	20	
Fatigue	1	0	
Dyspnoe	0	1	
Leg pain	2	0	
Time to ending (sec)	432±67	395±81	0.42

Supplementary Table III. Other medications that might interact with the metabolism of clopidogrel. There was no significant difference in the usage of other therapeutics between the two cohorts excluding their modifying effect on these results.

Other drugs	BMS (n=28)	DES (n=21)	P-value
Proton-pump inhibitors, n (%)	21 (75)	15 (71)	0.78
NSAID, n (%)	2 (7)	1 (5)	0.09
Calcium channel blockers, n (%)	8 (29)	6 (28)	0.86
Beta-blockers, n (%)	25 (89)	19 (90)	0.81
Statin, n (%)	27 (96)	21 (100)	0.59
Warfarin, acenocumarol, n (%)	2 (7)	2 (9)	0.34